我们如何设计CAR - T细胞来克服耐药性?

IF 5.3 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Biologics : Targets & Therapy Pub Date : 2021-01-01 DOI:10.2147/BTT.S252568

Maya Glover, Stephanie Avraamides, John Maher

{"title":"我们如何设计CAR - T细胞来克服耐药性?","authors":"Maya Glover, Stephanie Avraamides, John Maher","doi":"10.2147/BTT.S252568","DOIUrl":null,"url":null,"abstract":"Chimeric antigen receptor (CAR) T cell therapy has achieved unrivalled success in the treatment of B cell and plasma cell malignancies, with five CAR T cell products now approved by the US Food and Drug Administration (FDA). However, CAR T cell therapies for solid tumours have not been nearly as successful, owing to several additional challenges. Here, we discuss mechanisms of tumour resistance in CAR T cell therapy and the emerging strategies that are under development to engineer CAR T cells to overcome resistance.","PeriodicalId":9025,"journal":{"name":"Biologics : Targets & Therapy","volume":null,"pages":null},"PeriodicalIF":5.3000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/52/56/btt-15-175.PMC8141613.pdf","citationCount":"11","resultStr":"{\"title\":\"How Can We Engineer CAR T Cells to Overcome Resistance?\",\"authors\":\"Maya Glover, Stephanie Avraamides, John Maher\",\"doi\":\"10.2147/BTT.S252568\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Chimeric antigen receptor (CAR) T cell therapy has achieved unrivalled success in the treatment of B cell and plasma cell malignancies, with five CAR T cell products now approved by the US Food and Drug Administration (FDA). However, CAR T cell therapies for solid tumours have not been nearly as successful, owing to several additional challenges. Here, we discuss mechanisms of tumour resistance in CAR T cell therapy and the emerging strategies that are under development to engineer CAR T cells to overcome resistance.\",\"PeriodicalId\":9025,\"journal\":{\"name\":\"Biologics : Targets & Therapy\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":5.3000,\"publicationDate\":\"2021-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/52/56/btt-15-175.PMC8141613.pdf\",\"citationCount\":\"11\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biologics : Targets & Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2147/BTT.S252568\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biologics : Targets & Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/BTT.S252568","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 11

摘要

嵌合抗原受体(CAR) T细胞疗法在治疗B细胞和浆细胞恶性肿瘤方面取得了无与伦比的成功，目前有五种CAR T细胞产品已获得美国食品和药物管理局(FDA)的批准。然而，由于一些额外的挑战，CAR - T细胞治疗实体肿瘤还没有那么成功。在这里，我们讨论了CAR - T细胞治疗中肿瘤耐药的机制，以及正在开发的设计CAR - T细胞以克服耐药的新兴策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

How Can We Engineer CAR T Cells to Overcome Resistance?

查看原文本刊更多论文

How Can We Engineer CAR T Cells to Overcome Resistance?

Chimeric antigen receptor (CAR) T cell therapy has achieved unrivalled success in the treatment of B cell and plasma cell malignancies, with five CAR T cell products now approved by the US Food and Drug Administration (FDA). However, CAR T cell therapies for solid tumours have not been nearly as successful, owing to several additional challenges. Here, we discuss mechanisms of tumour resistance in CAR T cell therapy and the emerging strategies that are under development to engineer CAR T cells to overcome resistance.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Biologics : Targets & Therapy MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

8.30

自引率

0.00%

发文量

审稿时长

16 weeks